Marta Grazzini

TL;DR: CTC detection corroborated by suitable molecular characterization may assist in the identification and monitoring of more appropriate therapies in melanoma patients and potentially improves patient management.

TL;DR: The present study suggests for the first time that exposure to β-blockers for 1 year or more is associated with a reduced risk of progression of thick malignant melanoma, indicating the need for larger epidemiological studies and randomized clinical trials.

TL;DR: These results confirm recent observation that propranolol-blockers protect patients with thick cutaneous melanoma from disease recurrence and Repurposing the vast arsenal of approved drugs with a nononcology primary purpose may prove an attractive and inexpensive strategy for offering more effective treatment options to patients with cancer.

TL;DR: The most common sites of breast carcinoma cutaneous manifestation are the chest wall and abdomen, but they can occur at the extremities and in the head/neck region.

TL;DR: The results confirm and strengthen previous findings that β-blocker use is associated with a reduced risk of melanoma recurrence and death and indicate the strong need for a randomized clinical trial to conclusively assess whetherβ-blockers afford protection against melanoma Recurrence andDeath.